Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD
In this interview, Dr. Thomas Abrams of Harvard M…
Oncology Data Advisor · i3 Health
February 8, 20225m 52s
Audio is streamed directly from the publisher (podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.